Heart failure & cardiomyopathiesResearch article
Mortality in Patients With Hodgkin Lymphoma and Heart Failure
- Patients with classical Hodgkin lymphoma (cHL) and subsequent heart failure (HF) were matched 1:2 with comparators with HF
- matched 1:2 on sex, birth year, year of HF, and contact type (inpatient/outpatient)
- flexible parametric survival models adjusted for matching variables
Authors' conclusion
cHL was associated with higher all-cause mortality following HF diagnosis. CV-specific mortality was significantly higher for patients with HF ≥10 years after cHL, possibly highlighting the impact of late treatment toxicity, although careful interpretation is warranted given the strong competing risk of lymphoma-related deaths.
Study context
- Population
- Patients with classical Hodgkin lymphoma (cHL) and subsequent heart failure (HF), and comparators with HF, 2000 to 2022patients with cHL 257 · comparators 514
- Participants
- 257 vs 514
- Comparison
- all-cause mortality following HF diagnosis between patients with prior cHL and comparators
- cHLn = 257
- comparatorsn = 514reference
Main finding
As reported in the abstract
Deaths · median follow-up of 2.5 years for cHL and 3.3 years for comparators
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause mortality · higher with prior cHL | 1.81 (1.44–2.26) | |
| CV-specific mortality (explorative outcome) · overall; did not differ | 1.17 (0.78–1.75) | |
| CV-specific mortality (explorative outcome) · patients with HF ≥10 years after cHL | 3.13 (1.71–5.73) | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | cHL | comparators | Estimate |
|---|---|---|---|
| Cause of death | |||
| Lymphoma-related death | 40% | Not reported in the abstract | |
| CV death | Not reported in the abstract | 42% |
Original publication
Mortality in Patients With Hodgkin Lymphoma and Heart Failure. JACC Adv. Published 22 July 2026. doi:10.1016/j.jacadv.2026.103058
Summarised from the published abstract; every number is checked against it